PG
NVO

Proffitt & Goodson’s Novo Nordisk NVO Stock Holding History

Proffitt & Goodson’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,524
Closed -$175K – 272
2025
Q1 		$175K Buy
2,524
+280
+12% +$23.1K 0.03% 110
2024
Q4 		$193K Buy
2,244
+39
+2% +$4.22K 0.03% 106
2024
Q3 		$263K Buy
2,205
+49
+2% +$6.54K 0.04% 103
2024
Q2 		$308K Buy
2,156
+10
+0.5% +$1.32K 0.05% 95
2024
Q1 		$276K Buy
2,146
+2,046
+2,046% +$244K 0.05% 98
2023
Q4 		$10.3K Buy
+100
New +$9.89K ﹤0.01% 184

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Proffitt & Goodson's NVO Position: Q2 2025 in Review

Proffitt & Goodson sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 2,524 shares — an estimated $175K sold.

Proffitt & Goodson first reported a position in NVO in Q4 2023 and held it in 6 quarters. The position peaked at $308K in Q2 2024. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • Proffitt & Goodson reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • Proffitt & Goodson sold 2,524 Novo Nordisk shares in Q2 2025, an estimated $175K.
  • Proffitt & Goodson first reported a position in Novo Nordisk in Q4 2023 and held it in 6 quarters.
  • Proffitt & Goodson's Novo Nordisk position peaked at $308K in Q2 2024.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Proffitt & Goodson's 13F filing for Q2 2025, filed 23 Jul 2025.